Slow Parkinson progression through lifestyle

Trial ID
NCT07443293
Official Title
IMPACT 360 Study for Parkinson's Disease
Goal
Slow Parkinson progression through lifestyle
Phase
PHASE2
Status
RECRUITING
Sponsor
University of British Columbia
Study Type
INTERVENTIONAL
Enrollment
60 participants
Conditions
Parkinson's Disease (PD), REM Sleep Behavior Disorder
Interventions
Exercise, Meditation, Diet

Plain-Language Summary

IMPACT 360 is testing whether a coordinated program of exercise, meditation, and a brain-healthy diet can improve motor symptoms, reduce REM sleep behavior disorder events, and support thinking and overall quality of life in people with early Parkinson's or isolated RBD. The program pairs guided physical training to build strength, balance, and endurance, mindfulness meditation to lower stress and improve sleep and attention, and a MIND-style diet to reduce inflammation and support brain cells; these lifestyle changes are meant to complement, not replace, medications like levodopa. The study is enrolling adults 40 to 85 with early-stage Parkinson's (Hoehn and Yahr 1-2) or polysomnography-confirmed RBD who can follow instructions and use a smartphone and a computer for remote sessions. People with significant cognitive impairment (MoCA <21), medical or cardiac contraindications to exercise, current heavy exercisers or those who already completed an MBSR course or score high on the MIND diet, or anyone with MRI contraindications are excluded.

Locations

  • University of British Colombia, Vancouver, British Columbia, Canada

Frequently Asked Questions

What is this trial testing?
This trial is studying Exercise. IMPACT 360 is testing whether a coordinated program of exercise, meditation, and a brain-healthy diet can improve motor symptoms, reduce REM sleep behavior disorder events, and support thinking and overall quality of life in people with early Parkinson's or isolated RBD. The program pairs guided physical training to build strength, balance, and endurance, mindfulness meditation to lower stress and improve sleep and attention, and a MIND-style diet to reduce inflammation and support brain cells; these lifestyle changes are meant to complement, not replace, medications like levodopa. The study is enrolling adults 40 to 85 with early-stage Parkinson's (Hoehn and Yahr 1-2) or polysomnography-confirmed RBD who can follow instructions and use a smartphone and a computer for remote sessions. People with significant cognitive impairment (MoCA <21), medical or cardiac contraindications to exercise, current heavy exercisers or those who already completed an MBSR course or score high on the MIND diet, or anyone with MRI contraindications are excluded.
Who can participate?
Participants must be between 40 Years and 85 Years.
Where is this trial located?
This trial is recruiting at 1 location.
Does it cost anything to join?
No. There is no cost to participate. Study-related care and treatment are provided at no charge.
How long does the trial last?
This Phase 2 trial is estimated to last approximately 2 years and 7 months.

View on ClinicalTrials.gov